Advanced search
Publication Cover
Emerging Microbes & Infections Volume 10, 2021 - Issue 1
Submit an article Journal homepage
4,676
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody

Xianmin Menga Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1747-7783
ORCID Icon,
Peipei Wangb Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of China
,
Yanqing Xionga Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
,
Yijun Wua Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
,
Xiaoyan Lina Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
,
Song Lub Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of China
,
Ruowan Lib Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of China
,
Bei Zhaob Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of China
,
Jing Liub Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of China
,
Shaoqing Zengb Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of China
,
Liyan Zenga Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
,
Yan Wua Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
,
Yan Lua Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of China
,
Jinchao Zhangb Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of China
,
Datao Liub Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of ChinaCorrespondence[email protected]
,
Shuhai Wangb Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, People’s Republic of ChinaCorrespondence[email protected]
&
Hongzhou Lua Shanghai Public Health Clinical Center, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8308-5534
ORCID Icon show all
Pages 1638-1648 | Received 29 May 2021, Accepted 23 Jul 2021, Published online: 18 Aug 2021

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jingjing Zhang, Han Zhang & Litao Sun. (2022) Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?. mAbs 14:1.
Read now

Articles from other publishers (10)

Hazael Ramiro Ceja-Gálvez, Francisco Israel Renteria-Flores, Ferdinando Nicoletti, Jorge Hernández-Bello, Gabriela Macedo-Ojeda & José Francisco Muñoz-Valle. (2023) Severe COVID-19: Drugs and Clinical Trials. Journal of Clinical Medicine 12:8, pages 2893.
Crossref
Aline de Almeida Oliveira, Diana Praia Borges Freire, Ana Rodrigues de Andrade, Amanda de Miranda Marques, Luciana da Silva Madeira, José Procópio Moreno Senna, Ivna Alana Freitas Brasileiro da Silveira & Beatriz de Castro Fialho. (2023) The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19. Journal of Pharmaceutical Innovation.
Crossref
Xiwei Ji, Xiangrui Meng, Xiao Zhu, Qingfeng He & Yimin Cui. (2022) Research and development of Chinese anti-COVID-19 drugs. Acta Pharmaceutica Sinica B 12:12, pages 4271-4286.
Crossref
Venkateshan S. Prativadibhayankaram, Lawrence Soon-U Lee, David Lye, Xu Xiaoying, Ranjani Nellore, Vishal Pendharkar, Hannes Hentze, Siyu Guan, Benjamin J. Ayers, Shirley G. K. Seah, De Hoe Chye, Najwa S. N. Talib, Nivashini Kaliaperumal, Wei Yee Ong, Zi Xin Wong, Veonice B. Au, Anshula Alok, John E. Connolly, Jerome D. Boyd-Kirkup, Piers J. Ingram, Brendon J. Hanson, Kantharaj Ethirajulu, Damian O’Connell & Conrad E. Z. Chan. (2022) First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults. Infectious Diseases and Therapy 11:5, pages 1999-2015.
Crossref
Manojit Bhattacharya, Srijan Chatterjee, Bidyut Mallik, Ashish Ranjan Sharma & Chiranjib Chakraborty. (2022) Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective. Vaccines 10:10, pages 1612.
Crossref
Aysan Moeinafshar, Niloufar Yazdanpanah & Nima Rezaei. (2022) Immune-based therapeutic approaches in COVID-19. Biomedicine & Pharmacotherapy 151, pages 113107.
Crossref
Henning Gruell, Kanika Vanshylla, Timm Weber, Christopher O. Barnes, Christoph Kreer & Florian Klein. (2022) Antibody-mediated neutralization of SARS-CoV-2. Immunity 55:6, pages 925-944.
Crossref
Qianqian Li, Mengyi Zhang, Ziteng Liang, Li Zhang, Xi Wu, Chaoying Yang, Yimeng An, Jincheng Tong, Shuo Liu, Tao Li, Qianqian Cui, Jianhui Nie, Jiajing Wu, Weijin Huang & Youchun Wang. (2022) Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD. MedComm 3:2.
Crossref
William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt & Lila M. Strohl. (2022) Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs 36:3, pages 231-323.
Crossref
Yuzhou Gui, Chengyin Yu, Jiaye Zhou, Liang Xin, Ze Chen, Tiejiong Fan, Shuang Lu, Jingying Jia & Gangyi Liu. (2022) Development and validation of a ligand-binding assay for quantification of the F(ab')2 antivenom of Daboia russelii siamensis in human serum and its application to a phase I clinical study. Journal of Pharmaceutical and Biomedical Analysis 212, pages 114645.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.